Search

Displaying results 2851 - 2860 of 7452 in total
  1. Drug

    ANA975

    go.drugbank.com/drugs/DB06490
    Experimental

    ANA975 is a toll-like receptor 7 agonist that is developed for the treatment of hepatitis C.

  2. Drug

    Carbon dioxide

    go.drugbank.com/drugs/DB09157
    ApprovedInvestigationalVet approved

    during bodily investigations, to inflate body cavities during surgery (such as key-hole surgery), and in solid form (dry ice) for freezing of tissue and removal of warts.

  3. Drug

    Nalbuphine

    go.drugbank.com/drugs/DB00844
    ApprovedInvestigational

    It appears to be an agonist at kappa opioid receptors and an antagonist or partial agonist at mu opioid receptors.

    Categories: Heterocyclic Compounds with 4 or More Rings
  4. Drug

    Tolrestat

    go.drugbank.com/drugs/DB02383
    ApprovedWithdrawn

    Tolrestat (INN) (AY-27773) is an aldose reductase inhibitor which was approved for the control of certain diabetic complications. … While it was approved for marketed in several countries, it failed a Phase III trial in the U.S. due to toxicity and never received FDA approval.

  5. Drug

    Ferrous ascorbate

    go.drugbank.com/drugs/DB14490
    ApprovedWithdrawn

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Amineptine

    go.drugbank.com/drugs/DB04836
    ApprovedIllicitWithdrawn

    The Food and Drug Administration suspended the marketing authorisation for Survector in 1999 and France withdrew it from the market, however several developing countries continued to produce it up until

  7. Drug

    Ertugliflozin

    go.drugbank.com/drugs/DB11827
    ApprovedInvestigational

    Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 20...

  8. Drug

    Odronextamab

    go.drugbank.com/drugs/DB16684
    ApprovedInvestigational

    [A254192] Odronextamab received its first approval in the European Union on August 26, 2024, for the treatment of relapsed or refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma … Odronextamab is a hinge-stabilized, fully human immunoglobulin G4 (IgG4)-based CD20×CD3 bispecific antibody currently evaluated for the treatment of relapsed/refractory (R/R) B-Cell non-Hodgkin lymphoma

  9. Drug

    Exagamglogene autotemcel

    go.drugbank.com/drugs/DB15572
    ApprovedInvestigational

    [L49681] In September 2024, the drug was approved by Health Canada for the same indications. [L52850] … It was approved by the FDA in December 2023 for the treatment of patients with SCD with recurrent vaso-occlusive crises.

  10. Drug

    SN-38

    go.drugbank.com/drugs/DB05482
    Investigational

    7-ethyl-10-hydroxycamptothecin (SN 38) is a liposomal formulation of the active metabolite of Irinotecan [DB00762], a chemotherapeutic pro-drug approved for the treatment of advanced colorectal cancer